前沿速览021期| CAR-T治B淋 前沿览新知
01
儿童、青少年和年轻成人患者中复发/难治性B细胞非霍奇金淋巴瘤的疗法
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults
第一作者：Gardenswartz A
J Natl Compr Canc Netw (IF=14.8). 2024 Jun 18:1-7.
全文网址：https://jnccn.org/view/journals/jnccn/aop/article-10.6004-jnccn.2024.7006/article-10.6004-jnccn.2024.7006.xml
02
表达C1QB巨噬细胞的胆固醇外流与原发难治性弥漫性大B细胞淋巴瘤对CAR-T细胞疗法耐药相关
Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma
第一作者：Yan ZX
Nat Commun (IF=14.7). 2024 Jun 18;15(1):5183.
全文网址：https://www.nature.com/articles/s41467-024-49495-4
03
通过IFN-γ调节的VISTA的表达控制着内源性T细胞的功能，并与CD19 CAR-T细胞治疗B细胞恶性肿瘤小鼠的疗效相关
Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice
第一作者：Tang D
J Immunother Cancer (IF=10.3). 2024 Jun 25;12(6):e008364.
全文网址：https://jitc.bmj.com/content/12/6/e008364.long
04
CDK9抑制剂enitociclib可克服BTK抑制剂和CAR-T治疗套细胞淋巴瘤的耐药性
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
第一作者：Jiang V
Biomark Res (IF=9.5). 2024 Jun 18;12(1):62.
全文网址：https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00589-7
05
Brexucabtagene autoleucel治疗复发/难治性套细胞淋巴瘤：DESCAR-T登记研究中的意向性治疗使用情况
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
第一作者：Herbaux C
Haematologica (IF=8.2). 2024 Jun 20.
全文网址：https://haematologica.org/article/view/haematol.2023.284786
06
与原发性大B细胞淋巴瘤和转化的低级别B细胞淋巴瘤相比，CD19 CAR-T细胞疗法在Richter转化中的疗效较低
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma
第一作者：Benjamini O
Haematologica (IF=8.2). 2024 Jun 20.
全文网址：https://haematologica.org/article/view/haematol.2023.284664
07
Tisagenlecleucel在患有复发/难治性B细胞淋巴瘤的儿童与年轻成人患者中的真实世界应用
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
第一作者：Bender JD
Blood Adv (IF=7.4). 2024 Jun 25:bloodadvances.2024012928.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024012928/516711/Real-world-use-of-tisagenlecleucel-in-children-and
08
采用非远程监控和早期CRS干预策略进行CAR-T治疗的门诊管理
Outpatient Administration of CAR T-cell Therapies Using a Strategy of No Remote Monitoring and Early CRS Intervention
第一作者：Furqan F
Blood Adv (IF=7.4). 2024 Jun 18:bloodadvances.2024013239.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013239/516586/Outpatient-Administration-of-CAR-T-cell-Therapies
09
CAR-T细胞扩增：有害还是有益？
CAR T-cell expansion: harmful or helpful?
第一作者：Lionel AC
Blood Adv (IF=7.4). 2024 Jun 25;8(12):3311-3313.
全文网址：https://ashpublications.org/bloodadvances/article/8/12/3311/516697/CAR-T-cell-expansion-harmful-or-helpful
10
将T细胞疗法纳入复发/难治性滤泡性淋巴瘤患者的标准治疗方案：综述
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review
第一作者：Fowler NH
Target Oncol (IF=4.4). 2024 Jun 19.
全文网址：https://link.springer.com/article/10.1007/s11523-024-01070-z
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.7-1 valid until 2026.7
供稿与审核：临床开发与医学部